Taku Naiki

54PUBLICATIONS
48CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (54)

|Jul 01, 2026
Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer.

|May 04, 2026
Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up.

|Apr 29, 2026
Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study.

|Mar 26, 2026
Enhanced magnetic hyperthermia using anti-PD-L1 antibody-conjugated magnetoliposomes in a murine subcutaneous bladder cancer model.

Masakazu Gonda, Noriyasu Kawai, Daiki Ishikawa

|Mar 09, 2026
A Rare Case of Clear Cell Carcinoma Associated With Papillary Cystadenoma Originating in the Epididymis.

Hiroko Suzuki, Taku Naiki, Takuzi Tsuyuki

|Feb 26, 2026
Sustained Drug-Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone-Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide.

Yoshihisa Mimura, Takaomi Sanda, Rei Unno

Pageof 9

Frequent Collaborators

29 joint publications

Takahiro Yasui

13 joint publications

Shuzo Hamamoto

11 joint publications

Aya Naiki-Ito

11 joint publications

Atsushi Okada